IP Library Patent Application 12555732
Patent Application
App. No. 12/555,732

PHARMACEUTICAL COMPOUNDS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/555,732
Abstract

This application describes methods of treatment and/or prophylaxis of asthma that involve administration of dihydrotetrabenazine, and isomers and/or pharmaceutically acceptable salts thereof.

Claims (14)

1 . A method for the prophylaxis or treatment of asthma in a patient, which method comprises administering to the patient a therapeutically effective amount of a 3,11b cis-dihydrotetrabenazine, or a pharmaceutically acceptable salt thereof, to thereby treat asthma.

2 . The method of claim 1 , wherein the asthma is of any one or more of asthma types selected from the group consisting of allergic asthma, non-allergic asthma, late onset asthma, early-onset asthma, exercise-induced asthma, nocturnal asthma, cough variant asthma, work-related asthma, work aggravated asthma, occupational asthma, asthma induced by large molecular weight compounds, IgE-dependent asthma, asthma induced by low molecular weight compounds, IgE-independent asthma, reactive airways dysfunction syndrome, and inner city or urban asthma.

3 . The method of claim 1 , wherein the asthma is allergic asthma or exercise-induced asthma.

4 . The method of claim 1 , wherein the 3,11b-cis-dihydrotetrabenazine, or a pharmaceutically acceptable salt thereof, is a 2S,3S,11bR isomer of 3,11b-cis-dihydrotetrabenazine having the formula (Ia):

or a pharmaceutically acceptable salt thereof.

5 . The method of claim 1 , wherein the 3,11b-cis-dihydrotetrabenazine, or a pharmaceutically acceptable salt thereof, is a 2R,3R,11bS isomer of 3,11b-cis-dihydrotetrabenazine having the formula (Ib):

or a pharmaceutically acceptable salt thereof.

6 . The method of claim 1 , wherein the 3,11b-cis-dihydrotetrabenazine, or a pharmaceutically acceptable salt thereof, is a 2R,3S,11bR isomer of 3,11b-cis-dihydrotetrabenazine having the formula (Ic):

or a pharmaceutically acceptable salt thereof.

7 . The method of claim 1 , wherein the 3,11b-cis-dihydrotetrabenazine, or a pharmaceutically acceptable salt thereof, is a 2S,3R,11bS isomer of 3,11b-cis-dihydrotetrabenazine having the formula (Id):

or a pharmaceutically acceptable salt thereof.

8 . The method of claim 1 , wherein the 3,11b-cis-dihydrotetrabenazine is a free base.

9 . The method of claim 1 , wherein the pharmaceutically acceptable salt of 3,11b-cis-dihydrotetrabenazine is an acid addition salt.

10 . The method of claim 9 , wherein the salt is a methane sulphonate salt.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
SECURITY AGREEMENT Recorded Jul 18, 2011
From: VALEANT INTERNATIONAL (BARBADOS) SRL, A BARBADOS INTERNATIONAL SOCIETY WITH RESTRICTED LIABILITY; BIOVALE LABORATORIES INTERNATIONAL (BARBADOS) SRL, A BARBADOS INTERNATIONAL SOCIETY WITH RESTRICTED LIABILITY
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 026605/0801 →
CHANGE OF NAME Recorded Apr 1, 2011
From: BIOVAIL LABORATORIES INTERNATIONAL SRL
To: VALEANT INTERNATIONAL (BARBADOS) SRL
Reel/Frame 026072/0497 →
PATENT SECURITY RELEASE AGREEMENT Recorded Mar 14, 2011
From: GOLDMAN SACHS LENDING PARTNERS LLC
To: BIOVAIL INTERNATIONAL LABORATORIES SRL; BIOVAIL INTERNATIONAL LABORATORIES (BARBADOS) SRL
Reel/Frame 025950/0073 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 25, 2010
From: KWS BIOTEST LIMITED; WILLIAMS, NEIL ANDREW
To: BIOVAIL LABORATORIES INTERNATIONAL (BARBADOS) S.R.L.
Reel/Frame 025189/0585 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 25, 2010
From: DUFFIELD, ANDREW JOHN
To: BIOVAIL LABORATORIES INTERNATIONAL (BARBADOS) S.R.L.
Reel/Frame 025191/0274 →
SECURITY AGREEMENT Recorded Oct 4, 2010
From: BIOVAIL INTERNATIONAL LABORATORIES SRL; BIOVAIL INTERNATIONAL LABORATORIES (BARBADOS) SRL
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 025084/0022 →